our DIRECTORS and team
BRIAN LEEDMAN – NON-EXECUTIVE CHAIRMAN
Mr Leedman is formerly the Chairman (WA) of Ausbiotech, Founder and Executive Director of ResApp Health, Founder of Oncosil Medical and Biolife Sciences Limited (acquired by Imugene Limited) and Non-executive Director of Alcidion Corporation. He is presently the Chairman of NeuroScientific Biopharmaceuticals and Chairman of Nutritional Growth Solutions. He holds a BEc and an MBA from the University of Western Australia and has over 15 years’ experience in the biotechnology sector.
KRISTA BATES – NON-EXECUTIVE DIRECTOR
Ms Bates is an experienced non-executive and executive director of listed companies (Australian Stock Exchange and London Stock Exchange) and various private companies in multiple jurisdictions. She is commercially experienced, particularly talented in turnarounds, structuring, risk mitigation and strategic roll-out of commercial initiatives. She has an exceptional legal background with over 20 years’ experience in the legal market, with extensive experience working in emerging markets in both a commercial and legal capacity.
PROF. ALLAN CRIPPS AO – NON-EXECUTIVE DIRECTOR
Professor Cripps is currently a Professor Emeritus in the School of Medicine and Dentistry and the Menzies Health Institute Queensland at Griffith University, Australia. He is a member of the Infection and Immunity Research Team at the Menzies Health Institute Queensland at Griffith University, Australia. He is recognised nationally and internationally as a distinguished academic, clinical scientist and health services leader and has made significant contributions in immunology, vaccine development, diagnostics health services delivery and professional health education. The focus of Professor Cripps’ research activities over the last 5 decades have been in the field of immunology and inflammation. In 2015 he was awarded an Officer of the Order of Australia (AO) in recognition of his contributions to mucosal immunization, public health and higher education.
Professor Cripps has experience in the development of immunity in children and mucosal immune mechanisms, in recent years he has made a significant contribution to the field of immunology through translational research and human clinical studies. Professor Cripps is also a co-inventor on several patents in the fields of diagnostic technology and vaccine protein antigens for respiratory infection. He has published over 325 peer reviewed scientific papers and presented at many national and international scientific conferences.
MARK DAVIES – NON-EXECUTIVE DIRECTOR
Mr Davies graduated from the University of Western Australia with a Bachelor of Commerce. He has over 20 years’ experience in trading, investment banking and providing corporate advice. He worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital and more recently 1861 Capital.
Mr Davies specialises in providing corporate advice and capital raising services to emerging companies seeking business development opportunities and funding from the Australian market.
WINTON WILLESEE – NON-EXECUTIVE DIRECTOR
Mr Willesee is an experienced company director and company secretary. Mr Willesee has considerable experience with ASX listed and other companies over a broad range of industries having been involved with many successful ventures from early stage through to large capital development projects.
Mr Willesee holds a Master of Commerce, a Post-Graduate Diploma in Business (Economics and Finance), a Graduate Diploma in Applied Finance and Investment, a Graduate Diploma in Applied Corporate Governance, a Graduate Diploma in Education and a Bachelor of Business. He is a Fellow of the Financial Services Institute of Australasia, a Graduate of the Australian Institute of Company Directors, a Member of CPA Australia and a Fellow of the Governance Institute of Australia and the Institute of Chartered Secretaries and Administrators/Chartered Secretary.
DR ALEXANDRA ANDREWS – CHIEF EXECUTIVE OFFICER
Dr Andrews holds a Doctor of Philosophy (PhD) in Neuroscience from the University of Western Australia. She brings expertise in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.
Previously, she was Director of Operations at NeuroScientific Biopharmaceuticals Ltd. Throughout her career, Dr Andrews has worked closely with clinical researchers, investors and entrepreneurs, providing scientific and strategic input into clinical development plans and overseeing manufacturing. She brings commercial, transactional and project management experience, including via her earlier role at Linear Clinical Research where she focused on attracting partnerships with US biotechnology and pharmaceutical companies, and managing trial logistics.
ERLYN DAWSON – COMPANY SECRETARY
Mrs Dawson is an experienced company secretary, having held positions as company secretary for a number of ASX listed public companies across a diverse range of industries including resources, technology, industrials and health care.
Mrs Dawson has completed a Bachelor of Commerce (Accounting and Finance) and a Graduate Diploma of Applied Corporate Governance and is an Associate Member of both the Institute of Chartered Secretaries and Administrators and the Governance Institute of Australia.